<b>Introduction:</b> Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality. In 2019, GOLD strategy included blood eosinophils (Eos) as a biomarker that helps to identify the patients who would benefit from inhaled corticosteroid therapy. <b>Objective:</b> To describe Eos and clinical characteristics of patients with moderate to severe COPD in Bogotá, Colombia. <b>Methods:</b> Retrospective cohort study. Outpatients with confirmed moderate to severe COPD attending a comprehensive disease management program in two specialized centers between 2015 and 2017 were included. <b>Results:</b> 200 patients were selected (GOLD B=156, C=3, D=41); mean age was 77.9±7.9 years; 48% were women and 52% had biomass exposure as a risk factor. Mean FEV1/FVC was 53.4±9.8, mean FEV1 was 52.7%±20.7, and median Charlson comorbidity index was 6 (range 2 to 10). Geometric mean (GM) and standard deviation of absolute Eos (cell/mm3) was 197.6±2.1 (range 0-3020) in the general sample, 193.4±2.1 in the non-exacerbator phenotype, 173.8±2.1 in asthma-COPD overlap and 212.2±2.0 in frequent exacerbators. When stratified by risk factor, Eos GM was 172±1.9 for biomass (n=58), 244±2.2 for smoking (n=81) and 157±2.1 for biomass plus smoking (n=41). In the follow-up year 152 exacerbations were registered, 122 moderate and 30 severe. Mean annual exacerbation rate according to phenotype and Eos was: <b>Conclusions:</b> On this cohort, data suggests a variation in blood eosinophils within clinical phenotypes (higher in frequent exacerbator) and previous exposition (lower in biomass). Funding: GSK 207254 (PRJ2814).